▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #366 by analyst upside · 2026-09-27
PEPG
PepGen Inc.
Healthcare · Market Cap $179M · P/E 0x
ANALYST PRICE TARGET
+293.3%
implied upside to consensus target
Current Price $2.59
Consensus Target $10.19
Bull Target $20.0
Bear Target $2.5
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
7
Hold
0
Sell
1
52-Week Low $1.31
52-Week High $7.8
YTD Return -63.9%
FUNDAMENTALS
Market Cap $179M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.00
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.31
52-Week High $7.8
Current Price $2.59
Bear Target $2.5
Bull Target $20.0
● Now $2.59 ● Target $10.19
TRADING DATA
Avg Volume 943K
YTD Return -63.9%
Analyst Count 8
Consensus Buy
Upside to Target +293.3%
Last Updated 2026-09-27

ANALYST SUMMARY

PepGen Inc. (PEPG) is currently trading at $2.59 with a Wall Street consensus price target of $10.19, implying potential upside of 293.3% over the next 12 months. 8 analysts currently cover PEPG, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $20.0, while the most cautious has a target of $2.5.

PEPG operates in the Healthcare sector with a market capitalisation of $179M. The stock is down 63.9% year-to-date and is currently trading near the lower end of its 52-week range of $1.31 – $7.8.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PLX +304.4%
Protalix BioTherapeutics, Inc.
$219M · P/E 11.8x · Buy
XFOR +285.4%
X4 Pharmaceuticals, Inc.
$298M · P/E 2.2x · Buy
SABS +253.7%
SAB Biotherapeutics, Inc.
$299M · P/E 13.7x · Buy
QTTB +381.8%
Q32 Bio Inc.
$261M · P/E 2.8x · Buy
CCLD +257.7%
CareCloud, Inc.
$87M · P/E 29.3x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PEPG, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-09-09 31% win rate (48 calls)
Craig-Hallum ● Initiated
Buy 2026-06-16 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-05-13 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-04-01 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-03-31 Building track record
Oppenheimer ● Initiated
Outperform 2026-02-25 14% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-02-18 62% win rate (8 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-11-13 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →